Soluble interleukin-2 receptor decrease in the sera of HIV-infected patients treated with zidovudine

M. Galli, A. L. Ridolfo, C. Balotta, A. Riva, F. Cocchi, M. Musicco, V. M. Albarello Moroni

Research output: Contribution to journalArticle

Abstract

Laboratory parameters which are modified following administration of zidovudine are becoming increasingly useful in monitoring the efficacy of treatment of early stages of HIV-1 infection. The serum levels of soluble interleukin (sILR)-2 receptor, which have been reported to increase early in HIV-1 infection, were found to be significantly lower in 24 patients being treated with zidovudine than in 69 patients who were not treated, 28 of whom had CD4+ counts >400 x 10 6/l, and 41 6/l, respectively (P <0.0001) . A prospective study group of 33 subjects treated with zidovudine demonstrated a decrease in sIL-2R during therapy (base values 2113 ± 1131 versus 1444 ± 728 after 90 days of therapy; P

Original languageEnglish
Pages (from-to)1231-1235
Number of pages5
JournalAIDS (London, England)
Volume5
Issue number10
Publication statusPublished - 1991

Keywords

  • AIDS
  • HIV infection
  • Soluble interleukin-2 receptor
  • Zidovudine

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Fingerprint Dive into the research topics of 'Soluble interleukin-2 receptor decrease in the sera of HIV-infected patients treated with zidovudine'. Together they form a unique fingerprint.

  • Cite this

    Galli, M., Ridolfo, A. L., Balotta, C., Riva, A., Cocchi, F., Musicco, M., & Albarello Moroni, V. M. (1991). Soluble interleukin-2 receptor decrease in the sera of HIV-infected patients treated with zidovudine. AIDS (London, England), 5(10), 1231-1235.